Azacitidine-induced bullous pemphigoid-like localized toxic reaction
Authors:
- Rodrigo Brêtas Emerich NogueiraRNRodrigo Brêtas Emerich Nogueira
- Nelson Hidekazu TatsuiNTNelson Hidekazu Tatsui
- Laura Ramos de AlmeidaLALaura Ramos de Almeida
- Marcella Soares PincelliMPMarcella Soares Pincelli
- Celina Wakisaka MarutaCMCelina Wakisaka Maruta
- José Antonio SanchesJSJosé Antonio Sanches
- Elvira Deolinda Rodrigues Pereira VellosoEVElvira Deolinda Rodrigues Pereira Velloso
- Youko NukuiYNYouko Nukui
Open Access
- 26 February 2025
- journal article
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eRC0699
Abstract
Azacitidine is a hypomethylating agent recommended for the treatment of patients with high-risk myelodysplastic syndromes. Here, we report the case of a patient with myelodysplastic syndrome who was not eligible for allogeneic stem cell transplantation (allo-SCT) and presented with a rare and previously unreported cutaneous side effect after the use of subcutaneous azacitidine. We propose that changing the route of azacitidine administration from subcutaneous to intravenous could potentially decrease the occurrence of bullous pemphigoid-like localized toxic reactions in someKeywords
This publication has 10 references indexed in Scilit:
- Azacytidine-induced Sweet’s syndromeBMJ Case Reports, 2022
- Bullous pemphigoid‐like rash induced by bendamustineBritish Journal of Haematology, 2022
- Bullous eczema presenting as bullous pemphigoid-like eruption: A case seriesJAAD Case Reports, 2021
- Cutaneous adverse events induced by azacitidine in myelodysplastic syndrome patients: Case reports and a lesson from published work reviewThe Journal of Dermatology, 2020
- Bullous Pemphigoid–like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the LiteratureJournal of Immunotherapy, 2018
- Bullous Pemphigoid-like Skin Eruption during Treatment with Rivaroxaban: A Clinical Case StudyEuropean Journal of Case Reports in Internal Medicine, 2018
- Bullous pemphigoid‐like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumabAustralasian Journal of Dermatology, 2016
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Enoxaparin sodium–induced bullous pemphigoid-like eruption: a report of 2 casesJournal of the American Academy of Dermatology, 2004
- Cutaneous Reactions to AzacitidineArchives of Dermatology, 1991